STOCK TITAN

Absci to Participate in Upcoming Investor Conferences

(Neutral)
(Neutral)
Tags
conferences

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in multiple investor conferences in November 2024. The schedule includes the Truist Securities BioPharma Symposium in New York, Guggenheim Securities Inaugural Healthcare Innovation Conference in Boston, UBS Global Healthcare Conference in California, Stifel 2024 Healthcare Conference in New York, and Jefferies London Healthcare Conference in the UK. The company will participate in fireside chats and host one-on-one meetings. Live and archived webcasts will be available on Absci's investor relations website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

  • Truist Securities BioPharma Symposium (New York, NY)
    Hosting 1x1 meetings on Thursday, November 7
  • Guggenheim Securities Inaugural Healthcare Innovation Conference (Boston, MA)
    Fireside chat on Monday, November 11 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings
  • UBS Global Healthcare Conference (Rancho Palos Verdes, CA)
    Fireside chat on Wednesday, November 13 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time, and hosting 1x1 meetings
  • Stifel 2024 Healthcare Conference (New York, NY)
    Fireside chat on Monday, November 18 at 1:50 p.m. Eastern Time / 10:50 a.m. Pacific Time, and hosting 1x1 meetings
  • Jefferies London Healthcare Conference (London, UK)
    Hosting 1x1 meetings on Tuesday, November 19 and Wednesday, November 20

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com


FAQ

What investor conferences will Absci (ABSI) attend in November 2024?

Absci will attend five conferences: Truist Securities BioPharma Symposium, Guggenheim Securities Inaugural Healthcare Innovation Conference, UBS Global Healthcare Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference.

When is Absci's (ABSI) fireside chat at the UBS Global Healthcare Conference?

Absci's fireside chat at the UBS Global Healthcare Conference is scheduled for Wednesday, November 13 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time.

Where can investors watch Absci's (ABSI) conference presentations?

Investors can access live and archived webcasts of the fireside chat sessions on Absci's investor relations website at investors.absci.com.

Which international conference will Absci (ABSI) attend in November 2024?

Absci will attend the Jefferies London Healthcare Conference in London, UK, hosting one-on-one meetings on November 19 and 20.